Has Syeda Ali, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,520 in general payments to Syeda Ali, MD across 13 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Syeda Ali, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Syeda Ali, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Syeda Ali, MD

Nephrology · Pasadena, CANPI 1528051984

Payments from drug & device makers

$2,520in general payments, 2019–2025

Across 13 payments — averaging $193.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$2K
AstraZeneca$91
Bayer$70
Boehringer Ingelheim$31
Mallinckrodt Hospital Products Inc.$30
Amgen$29
plus $23 from 1 others

What the payments were for

Food & beverage$25593%
Education$207%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer	2	$2,245
AstraZeneca	4	$91
Bayer	3	$70
Boehringer Ingelheim	1	$31
Mallinckrodt Hospital Products Inc.	1	$30
Amgen	1	$29
Otsuka America Pharmaceutical, Inc.	1	$23

How this compares

$2,520 in reported general payments places this provider in the 60th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California →

Medicare billing

Part B allowed, 2024

$277,321

Medicare patients

285

Services billed

1,606

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
VelphoroSucroferric Oxyhydroxide	31	$58,214
Lanthanum Carbonate	11	$21,481
Cyclosporine	22	$11,584
Sevelamer Carbonate	69	$8,665
Tamsulosin Hcl	48	$868
Furosemide	142	$720
Amlodipine Besylate	86	$623
Finasteride	17	$443
Potassium Chloride	23	$441
Losartan Potassium	52	$419
Levothyroxine Sodium	17	$332
Allopurinol	43	$330
Metoprolol Succinate	22	$302
Simvastatin	20	$294
Donepezil Hcl	12	$274

Paid to pharmacies, not to this prescriber.

Other nephrology in Pasadena

Anjay RastogiLos Angeles$6.3M
Aamir JamalSan Dimas$5.5M
Mohamed El-ShahawyLos Angeles$4.4M
Kalpesh PatelCalabasas$3.6M
Jehad HaggiagiMission Hills$3.6M
Malvin YanSouth Gate$3.3M
Sohan DuaNorthridge$3.2M
Richard LafayetteStanford$3M
Anant DesaiGranada Hills$2.9M
Glenn ChertowStanford$2.2M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →